Biopharmaceuticals company Newron Pharmaceuticals has secured €38 million to advance novel therapies for patients with diseases of the central and peripheral nervous system. 

The capital, raised through newly issued shares, is set to accelerate the company’s ENIGMA-TRS Phase III programme, evaluating the safety and efficacy of evenamide as an add-on therapy to antipsychotics for treatment-resistant schizophrenia. 

“The investment by this group of existing and new shareholders is further validation of our development strategy for evenamide as the potential first add-on therapy in schizophrenia and as a new treatment option for the vast majority of patients who are poorly responding or resistant to available treatment options,” said Roberto Galli, CFO of Newron.  

“Importantly, this financing is expected to extend our operational runway well beyond the upcoming 12-week results from the ENIGMA-TRS 1 and 2 pivotal studies and support continued execution of our Phase III development programme.” 

Results from the ENIGMA-TRS 1 AND 2 studies are set to be announced in Q4 of 2026.